Close
Almac
Achema middle east

SGD Pharma Announces the Appointment of Fabio Invernizzi, General Manager West Business Unit

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

SGD Pharma, global primary glass packaging leader, has announced the appointment of Fabio Invernizzi as its new General Manager of its West BU.

The BU West includes SGD Pharma’s commercial activities for MEA, North and South America and our manufacturing footprint in Europe. Fabio joins the Group Executive Committee bringing over 15 years of experience in Commercial, Marketing and Business Development at a senior level for the life science industry. He joins SGD Pharma following his last position as Vice-President and EMEA BU Head of Capsules and Health Ingredients at Lonza. Prior to that role, Fabio led the Global Commercial & Business Development activities for the Capsules & Heath Ingredients Division at Lonza.

Commenting on his appointment, Fabio said: “In starting this next chapter, I am excited to join the experienced SGD Pharma team working alongside CEO Olivier Rousseau and the Executive Committee. I am eager to continue writing the success story of SGD Pharma with my team and colleagues – I believe we can bring the company to the next level of leadership in Europe in the Primary Pharmaceutical Packaging market. Together with the strong team in place, I also look forward to continuing to grow in the Americas.”

Fabio picks up the baton of West BU General Manager from Laurent Zuber, who will retire in January 2024 after a long lasting and successful career at Saint-Gobain and SGD Pharma. SGD Pharma would like to thank Laurent Zuber who led the commercial activities of the group and the General Management of the West BU with passion and dedication. The company also shares its deep gratitude to Laurent for building the customer relationships it has today and for expanding its product portfolio in molded and tubular.

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »